“…Together with the neuroprotective effects of baicalin reported by others [7,11,12,19,21,30,31], this study provides further supportive evidence for the potential use of baicalin as a therapeutic agent to reduce A-induced neuronal cytotoxicity. It is possible that baicalin may be beneficial to prevent or treat AD acting through the aforementioned mechanisms, however, further in vivo studies are needed to determine whether baicalin or its metabolites can indeed be transported across the blood brain barrier to reach brain tissue and accumulate up to a level for performing such functions, as the existing evidence of baicalin absorption and tissue distribution data published to date for baicalin are inconclusive [3,13,18,30,33].…”